Get started
Author

Brian L. Pearlman

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
2014 · Eric Lawitz, Mark S Sulkowski, et al. · The Lancet · 833
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial
2014 · Eric Lawitz, Edward Gane, et al. · The Lancet · 307
Sustained Virologic Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection: A Cure and So Much More
2011 · B. L. Pearlman, N. Traub · Clinical Infectious Diseases · 269
Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1–infected slow responders
2007 · Brian L. Pearlman, Carole Ehleben, et al. · Hepatology · 264
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
2017 · Ira M. Jacobson, Eric Lawitz, et al. · Gastroenterology · 244
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection
2016 · Paul Kwo, Edward J. Gane, et al. · Gastroenterology · 170
Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care
2012 · Brian L Pearlman · The Lancet Infectious Diseases · 109
Safety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV-TARGET
2014 · Stuart C. Gordon, Andrew J. Muir, et al. · Journal of Hepatology · 100
Hepatitis C Virus Infection in African Americans
2005 · Brian L. Pearlman · Clinical Infectious Diseases · 92
Hepatitis C treatment update
2004 · Brian L. Pearlman · The American Journal of Medicine · 82
Salicylate Intoxication: A Clinical Review
2009 · Brian L. Pearlman, Rashi Gambhir · Postgraduate Medicine · 69
The Combination of Simeprevir and Sofosbuvir Is More Effective Than That of Peginterferon, Ribavirin, and Sofosbuvir for Patients With Hepatitis C–Related Child's Class A Cirrhosis
2015 · Brian L. Pearlman, Carole Ehleben, et al. · Gastroenterology · 67
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial
2016 · Eric Lawitz, Nancy Reau, et al. · Gastroenterology · 53
Sofosbuvir and velpatasvir with or without voxilaprevir in direct‐acting antiviral‐naïve chronic hepatitis C: patient‐reported outcomes from POLARIS 2 and 3
2017 · Z. M. Younossi, M. Stepanova, et al. · Alimentary Pharmacology & Therapeutics · 47
PDF
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy
2019 · Anna S. Lok, Mark S. Sulkowski, et al. · Gastroenterology · 45
Metformin-associated lactic acidosis
1996 · Brian L. Pearlman, Andrew Z. Fenves, et al. · The American Journal of Medicine · 45
Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor
2013 · Brian L. Pearlman, Carole Ehleben · Hepatology · 44
Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection
2019 · Brian Pearlman, Michael Perrys, et al. · The American Journal of Gastroenterology · 42
P0886 : Efficacy and safety of grazoprevir/elbasvir +/- RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-edge treatment-experienced trial
2015 · P. Kwo, E. Gane, et al. · Journal of Hepatology · 40
Hepatitis C Infection: A Clinical Review
2004 · Brian L. Pearlman · Southern Medical Journal · 37
Predictors of fibrosis, clinical events, and mortality in MASLD: Data from the Global-MASLD study
2025 · Zobair M. Younossi, Leyla de Avila, et al. · Hepatology · 36
O165 Simeprevir Plus Sofosbuvir With/without Ribavirin in Hcv Genotype 1 Prior Null-responder/treatment-naive Patients (cosmos Study): Primary Endpoint (svr12) Results in Patients With Metavir F3–4 (cohort 2)
2014 · E. Lawitz, R. Ghalib, et al. · Journal of Hepatology · 34
Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study
2025 · Zobair M. Younossi, Leyla de Avila, et al. · Hepatology · 30
PDF
Hepatitis Delta Infection: A Clinical Review
2023 · Brian Pearlman · Seminars in Liver Disease · 28
PDF
Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease
2026 · Zobair M. Younossi, Markos Kalligeros, et al. · Clinical Gastroenterology and Hepatology · 24
Works count: 80
Citation count: 3,391
H-index: 24
I10-index: 39
Year
Topic
Type